

## HCN4 Charges Up the First Heart Field

Sean M. Stevens, William T. Pu

The concept of cardiac progenitors that persist late into heart development and potentially into postnatal life has ignited the interest of cardiac biologists. A little more than a decade ago, the prevailing notion of heart development centered on a cardiac tube containing immature cardiomyocytes that were committed to form specific segments of the mature heart.<sup>1</sup> During the past 15 years, this textbook view was overturned by the modern rediscovery<sup>2-4</sup> of the pioneering work of Viragh and Chalice<sup>5</sup> and others, which showed that the heart tube grows by addition of new cardiomyocytes to the arterial and venous poles by differentiation of noncardiomyocyte progenitors. Thus, at the time that the initial heart tube is first visible in the developing embryo through heart looping and the initiation of septation, cardiac progenitors that are present at both poles of the heart differentiate into cardiomyocytes and thereby significantly contribute to heart growth (Figure A).

### Article, see p 399

These later differentiating progenitors have been referred to as second heart field (SHF) progenitors and reside in the SHF located at the arterial and venous poles of the developing heart. Cai et al<sup>6</sup> made the seminal discovery that these SHF progenitors express the transcription factor Islet 1 (ISL1). *Isl1* is required in the progenitor cells for their normal activity but is shut off as the progenitors differentiate. ISL1<sup>+</sup> SHF progenitors are multipotent and differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells, the major lineages of the heart.<sup>7</sup> Development of Cre-based reagents allowed investigators to selectively label, isolate, and genetically manipulate these progenitors and their descendants in developing embryos. *Isl1*-based genetic reagents also proved valuable in isolating these progenitor cells and their descendants from differentiating embryonic stem cells, facilitating their in vitro analysis.<sup>7,8</sup> Cre-based genetic lineage tracing using most Cre-activated reporters indicated that Is11<sup>Cre</sup>-marked SHF progenitors contribute to the right ventricle, the outflow tract, and much of the atria, but little of the left ventricle.<sup>6</sup> These data suggested that most of these regions of the heart are generated by SHF progenitors after specification of the initial linear heart tube, although an important caveat is that the precise

boundaries of the Is11<sup>Cre</sup> domain depend on both the specific Is11<sup>Cre</sup> allele and the specific Cre-dependent reporter used.<sup>9,10</sup>

Relatively less is known about the first differentiating cardiomyocytes of the linear heart tube. By analogy to the terminology used for the SHF, it would be logical to define the first heart field (FHF) as the region of the embryo that houses the FHF progenitors, that is, those cardiac progenitors that first differentiate into the cardiomyocytes that populate the cardiac crescent and linear heart tube (Figure B). By inference based on the Is11<sup>Cre</sup> genetic fate map, descendants of the FHF generate most of the left ventricle and a subset of the atria. However, a lack of appropriate markers and genetic reagents has hindered studies of FHF progenitors and their descendants. This gap in knowledge has been particularly acute because these cells most closely match the needs of regenerative applications for acquired heart disease, which primarily affect the left ventricle.

In this issue of *Circulation Research*, Liang et al<sup>11</sup> report that the pacemaker channel gene *Hcn4* (hyperpolarization-activated nucleotide-gated cation channel 4) marks the FHF. Using a suite of *Hcn4* knockin alleles (*Hcn4*<sup>LacZ</sup>, *Hcn4*<sup>H2BGFP</sup>, and *Hcn4*<sup>CreERT2</sup>), Liang et al<sup>11</sup> show that *Hcn4* is expressed throughout the cardiac crescent at mouse embryonic day 7.5 in a population distinct from Is11<sup>+</sup> SHF progenitors. Subsequently, *Hcn4* is dynamically expressed in portions of the conduction system. Activation of *Hcn4*<sup>CreERT2</sup> with tamoxifen pulse-labeled at E7.5 allowed the fate of their descendants to be traced. As anticipated by inference from Is11<sup>+</sup> SHF progenitor genetic lineage tracing, the *Hcn4*<sup>CreERT2</sup>-labeled descendants were found primarily in the left ventricle. Additional descendants were found in the atria, coronary sinus, venous valves, and atrioventricular and sinoatrial nodes.

What types of cells in the E7.5 cardiac crescent express *Hcn4* and are labeled by *Hcn4*<sup>CreERT2</sup>? Are they cardiomyocyte progenitors, and if so are they multipotent like Is11<sup>+</sup> progenitors?<sup>7</sup> Or have they already committed to the cardiomyocyte lineage by the time they express *Hcn4* and are labeled at E7.5? Unfortunately, the study by Liang et al<sup>11</sup> does not directly address these points. After E9.5 *Hcn4*<sup>H2BGFP</sup> was expressed primarily in cardiomyocytes, but whether *Hcn4* expression is similarly confined to differentiated cardiomyocytes at E7.5 is unclear. Analysis of *Hcn4* or *Hcn4*-driven labels (eg, H2BGFP or preferably CreERT2) with cardiac progenitor (eg, *Mesp1*; *Nkx2-5*) or cardiomyocyte (eg, *Mlc2a*) lineage markers at E7.5 would have been helpful to address this point. Similarly, more detailed analysis of the cell lineages derived from E7.5 *Hcn4*<sup>CreERT2</sup>-labeled cells would have provided information about their fate and multipotency. As it is, we can unequivocally say that *Hcn4*<sup>CreERT2</sup> activated at E7.5 marks FHF derivatives (probably cardiomyocytes), but whether it marks FHF progenitors is uncertain based on the available data.

Broad expression of *Hcn4* in myocardial cells is rapidly extinguished after the linear heart tube stage so that by E16.5 it is confined to the conduction system, including the sinoatrial and

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association


From the Department of Cardiology, Boston Children's Hospital, Boston, MA (S.M.S.); and Department of Cardiology, Boston Children's Hospital, Boston, and Harvard Stem Cell Institute, Harvard University, Cambridge, MA (W.T.P.).

Correspondence to William Pu, MD, Department of Cardiology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115. E-mail wpu@pulab.org

(*Circ Res.* 2013;113:350-351.)

© 2013 American Heart Association, Inc.

*Circulation Research* is available at <http://circres.ahajournals.org>  
DOI: 10.1161/CIRCRESAHA.113.301981



**Figure. Cardiac progenitor populations in the developing heart.** **A**, Illustration of an E8.5 embryo highlighting the heart tube, containing differentiated cardiomyocytes and originating from the first heart field (FHF), and the second heart field (SHF), containing SHF progenitors. SHF progenitors differentiate into cardiac lineages to contribute to the ends of the heart tube (arrows). **B**, Lineage map of the developing heart. Around the time of gastrulation, a multipotent cardiac progenitor (likely *Mesp1*<sup>+</sup>) gives rise to *Isl1*<sup>+</sup> SHF progenitors and possibly an FHF progenitor (yet to be identified). SHF progenitors yield most of the right ventricle (RV), outflow tract (OFT), atria, and sinoatrial node (SAN). FHF cardiomyocyte derivatives, arising from the hypothetical FHF progenitor or directly from *Mesp1*<sup>+</sup> progenitors, express *HCN4* at the cardiac crescent stage. These cells ultimately yield most of the left ventricle (LV) and portions of the atria and the cardiac conduction system, including the atrioventricular node, bundle of His, and the bundle branches. AVN indicates atrioventricular node; BB, bundle branches; CM, cardiomyocyte; EC, endothelial cell; and SMC, smooth muscle cell.

atrioventricular nodes, the His bundle, the bundle branches, and the Purkinje fibers.<sup>11</sup> These data, consistent with findings based on a previously reported *Hcn4*<sup>CreERT2</sup> allele,<sup>12</sup> suggest that *Hcn4*-driven alleles will be useful tools to label and isolate conduction system cells at later stages of heart development. As pointed out by Liang et al,<sup>11</sup> Tam pulse labeling at these later stages should not be confused with descent from FHF but rather reflects the dynamic nature of *Hcn4* expression in different myocardial compartments.

An important use of cardiac lineage markers is to permit isolation of cardiac cell types from pluripotent stem cell differentiation systems, where there is a paucity of anatomic information to facilitate the segregation of populations. It would be desirable, for instance, to differentiate embryonic stem cells and isolate FHF progenitors or their derivatives. Whether this will be possible with *Hcn4* remains to be determined. The dynamic pattern of *Hcn4* expression suggests that precisely staged differentiation systems and a collection of multiple markers will be required to permit isolation of the equivalent of the labeled cardiac crescent cells and their derivatives. Interestingly, because *Hcn4* is a transmembrane channel, it is possible that its extracellular epitopes could be used as a cell surface marker to permit isolation of *Hcn4*<sup>+</sup> cells without the need for genetic modification.

During the past decade, considerable advances have been made in elucidating the lineage map of heart development (Figure B). Retrospective lineage mapping approaches have defined 2 distinct cardiac lineages that bifurcate from a common cardiac progenitor probably at or soon after gastrulation.<sup>13</sup> This common cardiac progenitor, likely marked by *Mesp1*,<sup>14,15</sup> differentiates into *Isl1*<sup>+</sup> SHF progenitors, which subsequently differentiate to yield the right ventricle, outflow tract, and portions of the atria and conduction system. Conceptually, the common *Mesp1*<sup>+</sup> progenitor also gives rise to an FHF progenitor, which then differentiates to yield the left ventricle and other portions of the atria and conduction

system. Evans, Liang, and colleagues have advanced the field by providing a means to label and isolate these FHF derivatives from embryos. In the future, it will be important to determine whether the *Hcn4*-expressing cells are already committed cardiomyocytes, and if so it will be important to develop means to isolate the hypothetical FHF progenitors. Alternatively, it is possible that *Mesp1*<sup>+</sup> progenitors differentiate directly into committed *Hcn4*<sup>+</sup> cardiomyocytes without a defined progenitor intermediate. It will also be crucial to determine whether and how *Hcn4* might be used to isolate bona fide left ventricular cardiomyocytes or their precursors from pluripotent stem cell cultures and whether the kinetics of human cardiogenesis also permit *HCN4* to be used for this purpose in human pluripotent stem cell differentiation.

## Sources of Funding

W.T. Pu was supported by National Institutes of Health (R01 HL094683 and U01 HL100401) and by charitable support from Gail Federici Smith, Edward Marram, and Karen Carpenter.

## Disclosures

None.

## References

- Srivastava D, Olson EN. A genetic blueprint for cardiac development. *Nature*. 2000;407:221–226.
- Virágh S, Challice CE. Origin and differentiation of cardiac muscle cells in the mouse. *J Ultrastruct Res*. 1973;42:1–24.
- Kelly RG, Brown NA, Buckingham ME. The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. *Dev Cell*. 2001;1:435–440.
- Mjaatvedt CH, Nakaoka T, Moreno-Rodriguez R, Norris RA, Kern MJ, Eisenberg CA, Turner D, Markwald RR. The outflow tract of the heart is recruited from a novel heart-forming field. *Dev Biol*. 2001;238:97–109.
- Waldo KL, Kumiski DH, Wallis KT, Stadt HA, Hutson MR, Platt DH, Kirby ML. Conotruncal myocardium arises from a secondary heart field. *Development*. 2001;128:3179–3188.
- Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J, Evans S. *Isl1* identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev Cell*. 2003;5:877–889.
- Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, Qiang Y, Bu L, Sasaki M, Martin-Puig S, Sun Y, Evans SM, Laugwitz KL, Chien KR. Multipotent embryonic *Isl1*<sup>+</sup> progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell*. 2006;127:1151–1165.
- Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, Lin LZ, Cai CL, Lu MM, Reth M, Platoshyn O, Yuan JX, Evans S, Chien KR. Postnatal *Isl1*<sup>+</sup> cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature*. 2005;433:647–653.
- Ma Q, Zhou B, Pu WT. Reassessment of *Isl1* and *Nkx2-5* cardiac fate maps using a *Gata4*-based reporter of Cre activity. *Dev Biol*. 2008;323:98–104.
- Sun Y, Liang X, Najafi N, Cass M, Lin L, Cai CL, Chen J, Evans SM. *Isl1* is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells. *Dev Biol*. 2007;304:286–296.
- Liang X, Wang G, Lin L, Lowe J, Zhang Q, Bu L, Chen Y, Chen J, Sun Y, Evans SM. *HCN4* dynamically marks the first heart field and conduction system precursors. *Circ Res*. 2013;113:399–407.
- Hoels E, Stieber J, Herrmann S, Feil S, Tybl E, Hofmann F, Feil R, Ludwig A. Tamoxifen-inducible gene deletion in the cardiac conduction system. *J Mol Cell Cardiol*. 2008;45:62–69.
- Meilhac SM, Esner M, Kelly RG, Nicolas JF, Buckingham ME. The clonal origin of myocardial cells in different regions of the embryonic mouse heart. *Dev Cell*. 2004;6:685–698.
- Bondué A, Lapouge G, Paulissen C, Semeraro C, Iacovino M, Kyba M, Blanpain C. *Mesp1* acts as a master regulator of multipotent cardiovascular progenitor specification. *Cell Stem Cell*. 2008;3:69–84.
- Bondué A, Tännler S, Chiapparato G, Chabab S, Ramalison M, Paulissen C, Beck B, Harvey R, Blanpain C. Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. *J Cell Biol*. 2011;192:751–765.

# Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION



## HCN4 Charges Up the First Heart Field Sean M. Stevens and William T. Pu

*Circ Res.* 2013;113:350-351

doi: 10.1161/CIRCRESAHA.113.301981

*Circulation Research* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2013 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the  
World Wide Web at:

<http://circres.ahajournals.org/content/113/4/350>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation Research* is online at:  
<http://circres.ahajournals.org/subscriptions/>